FDA Approvals, News & UpdatesLymphomaNewsworthy

Calquence Newest Treatment Approved for Mantle-Cell Lymphoma

In October 2017, the FDA accelerated the approval of Calquence for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.
December 2017 Vol 3 No 6

On October 31, 2017, the FDA accelerated the approval of Calquence (acalabrutinib; from AstraZeneca) for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy. Mantle-cell lymphoma is a rare and fast-growing type of non-Hodgkin lymphoma.

“Mantle cell lymphoma is a particularly aggressive cancer,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence. “For patients who have not responded to treatment or have relapsed, Calquence provides a new treatment option that has shown high rates of response for some patients in initial studies.”

This approval was based on a clinical trial of patients with mantle-cell lymphoma that showed that 81% of patients who received Calquence had a complete or partial response to this drug. Serious side effects with Calquence include bleeding, infections, and irregular heartbeat. Women who breastfeed should not take this drug. In addition, new cases of cancer occurred in some patients who used Calquence.

Recommended For You
Mantle-Cell LymphomaLymphoma
What Is Mantle-Cell Lymphoma?
Mantle-cell lymphoma is one of 70 subtypes of non-Hodgkin lymphoma. Although the precise cause is not known, the same genetic abnormality has been identified in a high percentage of patients.
Mantle-Cell LymphomaLymphoma
Diagnosing Mantle-Cell Lymphoma
Common signs and symptoms of mantle-cell lymphoma may be similar to other conditions. A comprehensive workup including a physical examination, lab tests, and imaging may be required to establish a definitive diagnosis and identify the disease stage.
Mantle-Cell LymphomaLymphoma
Initial Treatment of Mantle-Cell Lymphoma
A number of treatment options are available for patients with mantle-cell lymphoma. The specific choice of treatment may depend on the stage of the disease, symptoms, and the patient’s age and health status.
Mantle-Cell LymphomaLymphoma
Working with the Treatment Team
Patients and their loves ones should take part in key decisions regarding their care, and it is therefore important for patients to communicate their perspective during the shared treatment decision-making process.
Last modified: January 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.